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Recent pharmaceutical trials have demonstrated that slowing or reversing pathology
in Alzheimer’s disease is likely to be possible only in the earliest stages of disease,
perhaps even before significant symptoms develop. Pathology in Alzheimer’s disease
accumulates for well over a decade before symptoms are detected giving a large potential
window of opportunity for intervention. It is therefore important that imaging techniques
detect subtle changes in brain tissue before significant macroscopic brain atrophy.
Current diagnostic techniques often do not permit early diagnosis or are too expensive for
routine clinical use. Magnetic Resonance Imaging (MRI) is the most versatile, affordable,
and powerful imaging modality currently available, being able to deliver detailed analyses
of anatomy, tissue volumes, and tissue state. In this mini-review, we consider how MRI
might detect patients at risk of future dementia in the early stages of pathological change
when symptoms are mild. We consider the contributions made by the various modalities
of MRI (structural, diffusion, perfusion, relaxometry) in identifying not just atrophy (a
late-stage AD symptom) but more subtle changes reflective of early dementia pathology.
The sensitivity of MRI not just to gross anatomy but to the underlying “health” at the
cellular (and even molecular) scales, makes it very well suited to this task.
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INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent form of dementia (Jorm and Jolley, 1998), with
Mild Cognitive Impairment (MCI) often indicating a pre-AD phase (Albert et al., 2011), but even
at this point, brain pathology has been accumulating for many years (Jack et al., 2013). Hallmark
pathological changes in Alzheimer’s disease (AD) are amyloid plaques and neurofibrillary tangles
containing hyperphosphorylated tau (Perl, 2010) with associated cerebral amyloid angiopathy in
over 80% of cases (Ellis et al., 1996).
Early diagnosis of dementia is becoming critical as emerging treatments may delay progression
of disease only in the earliest stages (Liu-Seifert et al., 2015), before most patients are diagnosed.
The annualized conversion rate from MCI to AD is around 10% (Ward et al., 2013), but many
patients with symptoms of MCI will not develop dementia (even when there is some biomarker
evidence of AD, Jack et al., 2016) and some will develop non-AD dementia. So symptoms alone
cannot accurately predict those who have early stage AD. Current routine clinical tests include:
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1. Neuropsychology reveals a pattern of deficits consistent with
AD in the early stages, but changes are non-specific and an
individual’s baseline can be hard to ascertain;
2. Structural imaging Computed Tomography or MRI can
identify groups with MCI likely to progress to AD (Risacher
et al., 2009), but current implementations do not classify an
individual with sufficient accuracy. Although generally well
tolerated, MRI can be limited by symptoms of claustrophobia
and presence of metal implants.
3. Positron Emission Tomography (PET) and Single Photon
Emission Computed Tomography (O’Brien et al., 2014;
Archer et al., 2015; Weiner et al., 2015) Amyloid PET can
differentiate AD from healthy controls with over 95% accuracy
(albeit with substantial false positive rate) and also identifies
most people with MCI likely to develop AD (Vandenberghe
et al., 2013). Although not in routine clinical use, there are
also PET ligands that bind to phosphorylated-tau (FDDNP
molecule (Small et al., 2006) and 18F AV1451) that have
recently been shown to track progressive tau accumulation in
aging andAlzheimer’s disease Schöll et al. The expense of these
tests is prohibitive in most centers.
4. Lumbar puncture Low amyloid and raised tau in
cerebrospinal fluid (CSF) predict AD with 95% sensitivity
and 87% specificity after 4–6 years’ follow up (Hansson et al.,
2006), but lumbar puncture is an invasive test.
MRI is widely available and patients are routinely imaged
in diagnostic work up. Therefore, we predict that updated
application of MRI will become increasingly important for
accurate dementia diagnosis.
FUNDAMENTAL PRINCIPLES OF MRI
MRI exploits magnetic properties of atomic nuclei with the
quantum mechanical property of spin angular momentum,
commonly known as “the spin.” Hydrogen (1H) is an abundant
atom in vivo with a spin. As water molecules have two 1Hs and
our body is ∼70% water, 1H is an excellent reporter for MRI
(sodium = 23Na is the other inherent nucleus used for MRI
of living objects, not covered here). Thus, MR image detects
water in vivo in a spatially-specific manner where MR signal is
weighted to a given biophysical property of 1H according to the
data acquisition procedure.
Clinical MRI of human brain uses scanners with magnetic
field strength typically ranging from 1 Tesla (T) to 3T;
in research settings magnets up to 9.4T (ultra-high field
systems operate ≥ 7T) are used for humans. The strong
magnet produces “net magnetisation” of 1H nuclei that results
from “spin excess” in alignment in the magnetic field. The
amount of net magnetisation scales up with the magnetic field
strength so that the signal-to-noise ratio (SNR) in MR images
increases roughly linearly with the field. So, there is a clear
imperative toward higher magnetic fields as higher SNR can
yield higher spatial resolution, improved temporal resolution in
functional imaging, or improved access to microstructural
information in diffusion imaging (at a constant spatial
resolution).
Signal intensity in the MR image is chosen according to
dynamic properties of the 1H nuclei, such as rotational and
translational motions, that are weighted according to the MR
data acquisition parameters. Rotational motion of nuclei is
probed through MR relaxation, which is described by two
time constants: the longitudinal relaxation time or T1 and the
transverse relaxation time or T2. T1 and T2 are commonly
exploited for structural MRI at macroscopic scale, also known
as volumetry. It should be stressed that both quantitative T1
(Barazany and Assaf, 2012) and T2 (MacKay et al., 1994) can also
provide data indirectly from tissue microstructure.
Morphometry
In this section we will cover volumetry (which we define
as volume analysis of macroscopic brain structures), cortical
thickness and shape analyses [Voxel Based Morphometry
or parcellation not reviewed (See Whitwell et al., 2012 for
information; Yang et al., 2012)].
The volume of a tissue or subcortical structure in the brain
is reflective of the number of neurons, dendritic processes or
synapses (Schuff et al., 2009; Jack, 2012). Quantitation of volumes
is therefore sensitive to various diseases and their progression.
MRI is an excellent modality to quantify brain and subcortical
volumes and is widely used in assessment of suspected MCI
or AD (Jack et al., 2012; Weiner et al., 2015). MR volumetry
generally uses 3D T1-weighted data sets, which can be acquired at
a 1mm isotropic resolution in around 5min. Volumetric analysis
based on such data can readily be automated, for which various
fast and robust software packages exist (Dale et al., 1999; Tzourio-
Mazoyer et al., 2002; Fischl et al., 2004; Jack, 2012) and this would
enhance clinical practice if implemented in the near future.
Cortical thickness estimates (Li et al., 2015; Redolfi et al., 2015)
are straightforward from 3D T1-weighted images. It should be
noted that what is said about 3D T1-weighted images apply to
scans acquired at clinical field strengths. At ultra-high fields T1
becomes longer which has to be accounted for in setting data
acquisition parameters. The same brain region of two individuals
may atrophy by the same amount, but localized to different
particular subregions, yielding the same volume (and volume
loss) but different symptoms for the aﬄicted individuals; shape
analysis seeks to address this.
Functional MRI
Functional MRI (fMRI) most commonly probes haemodynamic
response, resulting from local decline in the ratio of
deoxyhaemoglobin-to-oxyhaemoglobin and increase in blood
volume elicited in response to “brain activation.” The so-called
Blood Oxygenation Level Dependent (BOLD) signal localizes
haemodynamic response to brain activation, the BOLD effect
influencing the transverse relaxation rates T2 and T
∗
2 . Reduction
of local magnetic gradients and increased blood volume prolong
parenchymal T2(
∗), which is recorded as a positive BOLD signal
by means of T2(
∗)-weighted MRI.
Haemodynamic responses due to experimental external events
result in task-activated BOLD fMRI from which inferences have
been made with regard to cognitive function. Fluctuations in
BOLD without an external trigger, the so-called resting state
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fMRI, allows indirect inference about intrinsic brain connectivity
and this may change as a result of neurodegenerative disease and
is discussed below.
Diffusion Tensor Imaging
Diffusion tensor imaging (DTI) seeks to image the translational
(thermal) motion of water, which is a tensor field (different in
different directions and different at every voxel of the image)
due to microstructural barriers to diffusion (e.g., cells/subcellular
structures) constraining the motion of water differently along
different directions (Basser and Jones, 2002). The translational
motion of water is probed by sensitizing the MR signal to
“diffusion” bymeans ofmagnetic field gradient-based approaches
(see Figure 1 for an example). Because of this DTI can inform
about the tissue microstructure at subvoxel resolution—it is the
cellular and subcellular architecture which constrains the motion
of water in vivo. Whilst DTI contains a wealth of information
from water diffusion in vivo, analysis often focuses on the
extraction of the mean diffusivity (MD) and fractional anisotropy
(FA), referred to as DTI metrics below, as well as axial and radial
diffusivity (Stebbins and Murphy, 2009; Amlien and Fjell, 2014;
Zhang et al., 2014). The MD refers to the average rate of diffusion
along the three axes of the diffusion tensor and is sensitive to
water content and overall tortuosity (level of “constraint” of
diffusion) of the environment. FA parameterises the extent to
which diffusion is different along the three axes of the diffusion
tensor, taking extreme values of zero when diffusion is the
same in all directions (as in CSF) and unity when constrained
entirely along a single direction (such as along a fiber tract).
DTI can be used to estimate axonal density and diameter in
white matter as indices of white matter integrity (Madden et al.,
2012).
MR Spectroscopy
Magnetic resonance spectroscopy (MRS) seeks to observe a
spectrum of resonance lines, each deriving from a unique spin
FIGURE 1 | Diffusion tensor MRI in Alzheimer’s research. Panel (A)
shows the directional information encoded by diffusion tensor imaging by color
(red: left-right, green: anterior-posterior, blue: head-foot) and fractional
anisotropy (high intensity implies high fractional anisotropy). Panel (B) shows
how the directional information may be represented in a deterministic
tractography analysis, and shows the regions consistently identified and
changing in AD (Blue: Corpus callosum, red: uncinate fasciculus, green:
superior lateral fasciculus).
state transition frequency. Although, there is much overlap of
lines in the magnetic resonance spectrum of an in vivo system,
which contains many molecules each with many spins, there
are still enough well resolved resonances deriving from unique
metabolites for it to be a very powerful method. A unique
feature of 1H MRS is that it reveals cell-specific metabolite
biomarkers, such as N-acetyl asparate (NAA) and myo-inositol
(Amlien and Fjell, 2014). The intensities or integrals of spectral
lines are directly informative of metabolite concentrations.
MRS can be performed with spatial specificity, recording a
spectrum from a voxel of choice within the brain (Oz et al.,
2014).
Relaxometry
Magnetic resonance relaxometry is the imaging of relaxation
parameters such as T1, T2, T
∗
2 , and T1ρ, describing various aspects
of the re-equilibration of the spin system after perturbation by
radiofrequency pulses. Like diffusion parameters, they essentially
describe the status of a tissue. Typically they take higher values
when a tissue is “unhealthy” due to oedema (more motile
water present) or when cells have been broken down, reducing
dephasing of magnetisation, thus prolonging signal lifetimes
quantified by T2 and T
∗
2 , and making water by and large more
motile, which increases all relaxation parameters.
Brain Perfusion
Brain perfusion, which is driven by cerebral blood flow, can be
detected by arterial spin labeling (ASL) MRI. In ASL MRI the
arterial blood entering the brain is magnetically labeled either
by radio frequency (RF)-field or RF-inversion pulse. The signal
decline between the non-labeled (“control”) and labeled ASL
images is proportional to the tissue perfusion and the signal
difference can be converted with appropriate procedures into
absolute units of blood perfusing a unit volume of tissue per
minute (Alsop et al., 2015).
BRAIN ATROPHY IN AD AND MCI
A slow decrease in total brain volume is part of physiological
aging (Peters, 2006). Both white matter (WM) and gray matter
(GM) decline in volume during normal aging (Sullivan et al.,
1995; Salat et al., 1999; Peters, 2006; Scahill and Fox, 2007) with
gray matter atrophy undergoing global atrophy accelerated in
insula, superior parietal gyri, central sulci, and cingulate sulci
and relative sparing in amygdala, hippocampi, and entorhinal
cortex. In contrast, global white matter does not decline, but
there are islands of accelerated decline particularly of white
matter areas to frontal lobes and thalamus (Good et al., 2001).
An increased rate of atrophy is predictive of AD (Jack, 2012),
though also of other forms of dementia (Chan et al., 2001).
An abnormal ratio of GM to cerebrospinal fluid (CSF) is also
suggestive of a disease processes (Sullivan et al., 1995; Salat et al.,
1999).
Hippocampal Atrophy in AD and MCI
Atrophy rates are different for different regions and tissues.
In particular, the hippocampus often suffers particularly severe
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atrophy in AD (Jack, 2012), and often (though not always)
before the outward display of cognitive symptoms. Volumetric
analysis of the whole HC has been shown to be an effective
biomarker for demonstrating short-term clinical decline in
AD (Landau et al., 2010; Ewers et al., 2012; Lehmann et al.,
2013; Jack et al., 2015) and also shows relative success
at predicting conversion from MCI to AD (Schuff et al.,
2012; Liu et al., 2013). Rate of atrophy has consistently
performed well in comparison to other biomarkers and cognitive
indices (Holland et al., 2012; Leung et al., 2013; Jack et al.,
2015).
However, the HC is a complex structure, composed of several
subfields (Figure 2), distinct in terms of cellular content and
connections with other brain regions (Duvernoy, 2005). Autopsy
data show that these are differentially vulnerable to AD pathology
(Braak and Braak, 1991; Jack et al., 2002; Silbert et al., 2003;
Fearing et al., 2007; Zhang et al., 2015).
An increasing body of recent research indicates that
the quantitation of individual subfield volumes has superior
sensitivity and specificity in detecting and distinguishing AD
and MCI, as well as other dementias (La Joie et al., 2013; Li
et al., 2013; Maruszak and Thuret, 2014; Perrotin et al., 2015). An
emerging picture is that the CA1 and subiculum subfields have
the highest diagnostic power in detecting early AD (de Flores
et al., 2015).
There is ongoing research to automate the labeling of
hippocampal subfields in MR images (Yushkevich et al., 2015).
Beyond the Hippocampus
Beyond the HC, temporal and parietal volumes can identify
healthy individuals who are at risk of future memory decline
(Chiang et al., 2011). Other areas including subfields within the
thalamus—a connectivity hub for the neocortex—are abnormal
FIGURE 2 | The human hippocampus. Image shows a 3D representation of
the right hippocampus with six subfields and a coronal MR image of the
hippocampal body with corresponding subfields. Segmentation as described
in (Wood et al., 2015). Red = CA1, Light blue = CA2, yellow = CA3,
blue = subiculum, pink = dentate gyrus, green = Stratum radiatum/stratum
lacunosum/ stratum moleculare (SR/SL/SM).
in established AD (Braak and Braak, 1991). A fascinating area
to consider for the future is how brain network disruption
including distributed brain areas might actually precede and
even propagate AD pathology (Kapogiannis and Mattson,
2011; Sotiropoulos et al., 2013). Thus, metabolic and network
biomarkers such as fMRI and DTI may become important.
However, currently medial temporal and parietal regions have
been shown to be individual regions most susceptible to changes
of early AD (Heckemann et al., 2011).
The medial temporal area Entorhinal cortex (EC), in
particular, is recognized as a region severely affected by AD
pathology and is reported to be the most heavily damaged cortex
in AD (Van Hoesen et al., 1991). EC atrophy is predicted to
occur prior to hippocampal damage and is one of the earliest
signs of disease manifestation. The rate of atrophy in the EC
correlates with severity of cognitive symptoms (Li et al., 2012)
and is considered predictive of conversion from MCI to AD
(Devanand et al., 2007).
Furthermore, AD patients display cortical thinning in
bilateral, frontal, parietal, and occipital lobes compared to
controls and thinner cortex in parts of the bilateral parietal
and precuneus region compared to frontotemporal dementia
(Du et al., 2007). A negative correlation between cognitive
performance and cortical thickness was also reported in these
regions (Du et al., 2007), indicating that cortical thickness in these
regions is a marker of disease severity.
BEYOND VOLUME: ANALYSIS OF SHAPE
The patterns of loss of cortical thickness from MRI agree with
those seen in autopsies and appear in early phase of AD in the
inferior temporal lobe cortex (Marshall et al., 2014), followed by
peri-ventricular structures prior to a more widespread cortical
thinning. Salat et al. reported that cortical thinning in AD
is associated with decrease in contrast-to-noise-ratio (CNR)
between gray and white matter in T1 images (Salat et al., 2011).
The decrease in CNR is thought to result from microstructural
changes in brain tissue, which are likely to precede loss of tissue
volume and could be earlier indication of imminent pathology
(Westlye et al., 2009; Callaghan et al., 2014).
Both local displacements and global shape alterations in the
hippocampus have been shown to distinguish AD from MCI
(Wang et al., 2003; Thompson et al., 2004; Ceyhan et al., 2011),
and identify MCI to AD conversion rates with 80% accuracy
(Costafreda et al., 2011). Involvement of the CA1 subfield has
been consistently reported in the latter studies, particularly in the
right hemisphere in agreement with detailed volumetric analysis
and autopsy findings.
INCREASED DIFFUSIVITY AND
DECREASED FRACTIONAL ANISOTROPY
ARE THE HALLMARKS OF MCI AND AD
The general picture from the use of MD and FA as diffusion
metrics is that MD is increased whereas FA is decreased in
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AD and MCI patients relative to controls. In a meta-analysis
of AD and MCI studies conducted up to 2010 (Sexton et al.,
2011), the largest MD effects were found to be localized to the
HC, temporal and parietal regions. The largest FA decreases
relative to controls have generally been found in the uncinate
fasciculus, superior lateral fasciculus and corpus callosum. More
recent work (Palesi et al., 2012; Hong et al., 2013; Jacobs
et al., 2013) has continued to reinforce these findings. It has
also been reported in recent studies that axial and radial
diffusivity show widespread increases in both MCI and AD,
and that these measures are more sensitive to dementia and
cognitive impairment than FA (Shu et al., 2011; Nir et al.,
2013). DTI has been shown to have superior patient/non-patient
classification capability relative to volumetric analysis alone
(Santillo et al., 2013) and in combination therewith (McMillan
et al., 2014).
DTI METRICS AND CEREBROSPINAL
FLUID (CSF) BIOMARKERS IN AD AND MCI
There has been work recently to relate levels of known AD
CSF biomarkers Tau and Amyloid. Although a consensus has
yet to be reached, there is an emerging picture that DTI is a
powerful complement to the use of CSF biomarkers (Clerx et al.,
2012).
CSF biomarkers have been variously related to increased
hippocampal MD in AD (Bendlin et al., 2012; Douaud et al.,
2013) and white matter FA in MCI (Selnes et al., 2013),
with the general conclusion that DTI measures are superior
predictors of AD than CSF biomarkers, and the use of
DTI and CSF biomarker quantitation in concert is superior
again.
RELAXOMETRY
A recent study quantifying T1ρ in the medial temporal lobe
(MTL) showed increased T1ρ in MTLWM and GM in AD (Haris
et al., 2011) and that its measurement, like DTI, surpassed the
sensitivity of CSF biomarkers Tau and Aβ42 in diagnosing AD,
though CSF biomarkers showed better specificity (Haris et al.,
2015).
FUNCTIONAL CONNECTIVITY (OR
RESTING-STATE MRI)
There has been increasing interest in recent years in resting-
state functional connectivity, where MRI is monitored by BOLD
contrast. A large literature now exists on resting state fMRI
applications in dementia (Zhou and Seeley, 2014). Whilst
the results have not yet fully converged, recent reviews of
applications in AD (Sheline and Raichle, 2013; Krajcovicova
et al., 2014) note consistent observations of alterations to
the default mode network, though many brain networks are
variously implicated. Interestingly, the relationship between
functional connectivity, brain volume and cognitive ability differs
during lifespan with, for example, cortico-striatal functional
connectivity being related to change in recall of episodic
memory in older adults more than younger people (Fjell et al.,
2015).
PERFUSION IMAGING AND AMYLOID
RELATED VASCULAR CHANGES
An emerging picture in AD research is the role of cerebral
perfusion, with vascular changes occurring early in disease
progression (Mazza et al., 2011). In particular, global and
regional cerebral hypoperfusion are associated with the disease,
though debate continues as to whether this is a cause or
effect (de la Torre, 2000). Either way, the observation that
AD is thereby linked to modifiable vascular risk factors has
attracted considerable attention. Hypoperfusion as measured
by ASL has been consistently observed in the posterior
cingulate, precuneus, inferior parietal, and lateral prefontal
cortices (Alsop et al., 2010; Wolk and Detre, 2012; Wierenga
et al., 2014). ASL findings compare well to FDG-PET (Musiek
et al., 2012), with recent data also suggesting the capacity
of ASL to add to diagnostic power, with distinct patterns
of perfusion in different dementias (Binnewijzend et al.,
2014).
As well as atherosclerotic changes in people with AD, blood
vessels can be affected by cerebral amyloid angiopathy or
damage from amyloid-modifying therapies (known as Amyloid
Related Imaging Abnormalities–ARIA). Such changes include
vasogenic oedema (visualized on T2 weight Fluid Attenuation
Inversion Recovery Sequences) and microhaemorrhages (visible
on T∗2 sequences such as Gradient Echo) (Sperling et al.,
2011).
SPECTROSCOPY
In the large literature on the use of 1H MRS in dementia,
consistent findings in AD include significantly reduced NAA, the
neuron-specific MRS biomarker, in the posterior cingulate and
bilateral hippocampus (Murray et al., 2014; Wang et al., 2015).
Similar to NAA, glutamate has been shown to be decreased in
these brain structures (Alsop et al., 2010). The glial metabolite,
myo-inositol, is increased in the posterior cingulate (PC) and
parietal GM (Wang et al., 2015; Murray et al., 2014). NAA
concentration in the posterior cingulate of MCI patients has
been reported to be intermediate between controls and AD
patients. Applications of MRS to MCI have found broadly
similar results, and additionally that choline was reduced in the
hippocampus but Choline/Creatine ratio raised in the PC. Myo-
inositol/creatine ratio was also raised in the hippocampus while
NAA was reduced in paratrigonal WM, hippocampus and PC
(Kantarci, 2013; Tumati et al., 2013; Zhang et al., 2015).
SUMMARY/CONCLUSION
Early detection and treatment of dementia is conceivable in the
coming generation and remains one of the most pressing current
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challenges for healthcare research. The contributions from
MRI are potentially substantial with, for example, automated
hippocampal subfield volumetrics and DTI already having
significant support for clinical application and relaxometry,
perfusion imaging and MRS being active areas of research
that could lead to clinical applicability. Future research
directions should concentrate on optimum combination
of available test for early accurate cost effective dementia
diagnosis.
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